Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
MCRB
MCRB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MCRB News
Seres Therapeutics Appoints New Executive Chair and Interim CEO
1d ago
seekingalpha
Seres Therapeutics Pauses SER-155 Investment Amid Funding Challenges
Feb 12 2026
seekingalpha
Seres Pauses SER-155 Phase 2 Study Amid Cost-Cutting Measures
Feb 12 2026
stocktwits
Seres Therapeutics Stock Declines Amid Strategic Shift
Feb 12 2026
Benzinga
Seres (MCRB) Third Quarter 2025 Earnings Call Summary
Nov 06 2025
NASDAQ.COM
Seres Receives Positive Input from FDA on Phase 2 Study Protocol for SER-155; Plans Workforce Reduction
Sep 23 2025
NASDAQ.COM
Seres Therapeutics reduces workforce by 25% to prolong cash reserves until Q2 2026.
Sep 23 2025
SeekingAlpha
Everything You Should Know About Seres Therapeutics (MCRB) Upgrade to Buy Rating
Sep 09 2025
NASDAQ.COM
Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost
Sep 09 2025
NASDAQ.COM
Robinhood Shares Surge Over 7%; Check Out 20 Stocks Making Moves in Premarket Trading
Sep 08 2025
Benzinga
Seres Therapeutics Rises Following News of Acquisition Proposal
Sep 08 2025
SeekingAlpha
Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript
Aug 07 2025
Newsfilter
Seres (MCRB) Q2 Loss Narrows 34%
Aug 07 2025
NASDAQ.COM
Seres Therapeutics CEO Eric Shaff To Resign, Thomas DesRosier And Marella Thorell To Be Co-CEOs
Jul 22 2025
NASDAQ.COM
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
May 08 2025
Benzinga
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
May 08 2025
Benzinga
Show More News
